325 completed, 121 terminated, 83 active not recruiting, 54 recruiting. 429 Phase 2, 212 Phase 1, 71 Phase 3, 13 Not applicable, 12 Phase 4.
Follow Rituxan: new trials by email Literature Review of Rituxan trials Research Report on Rituxan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | City of Hope Medical Center | 58 | 2026-12-21 | 2026-10-22 |
| Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma, Gastric Mucosa-Associated Lymphoid Tissue Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 35 | 2026-12-16 | 2026-09-29 |
| Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients Biospecimen Collection, Computed Tomography, Cyclophosphamide - Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma | Phase 1 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 20 | 2026-12-08 | 2026-07-20 |
| Rituximab for PTLD Prevention in Solid Organ Transplant Recipients With EBV DNAemia Rituximab - PTLD, Epstein Barr Virus (EBV) Infection | Phase 1 | Not yet recruiting | Jennifer Amengual | 28 | 2026-12-01 | 2026-09-17 |
| Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO) Loncastuximab tesirine, Rituximab or rituximab biosimilar - Post-transplant Lymphoproliferative Disorder | Phase 1 / Phase 2 | Not yet recruiting | University of Utah | 23 | 2026-11-01 | 2026-10-09 |
| Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma Biospecimen Collection, Cisplatin, Computed Tomography - Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma | Phase 1 | Not yet recruiting | National Cancer Institute (NCI) | 16 | 2026-10-30 | 2026-09-03 |
| Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 271 | 2026-10-30 | 2026-08-19 |
| Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma Rituximab, Tafasitamab, Biospecimen Collection - Classic Follicular Lymphoma, Grade 1 Follicular Lymphoma | Phase 2 | Recruiting | University of Washington | 30 | 2026-10-09 | 2026-10-15 |
| AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - AIDS-Related Diffuse Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 | Not yet recruiting | National Cancer Institute (NCI) | 15 | 2026-10-09 | 2026-08-13 |
| Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Adult Burkitt Lymphoma | Phase 2 | Not yet recruiting | AIDS Malignancy Consortium | 43 | 2026-09-17 | 2026-10-16 |
| Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD Rituximab (R), Eculizumab (Soliris®), Ravulizumab - NMOSD | Phase 4 | Recruiting | Massachusetts General Hospital | 540 | 2026-09-01 | 2026-09-24 |
| Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial Biospecimen Collection, Computed Tomography, Cyclophosphamide - Richter Syndrome, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 102 | 2026-08-04 | 2026-10-13 |
| Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Biopsy Procedure, Biospecimen Collection - Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Recruiting | City of Hope Medical Center | 43 | 2026-07-27 | 2026-08-28 |
| Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 84 | 2026-05-29 | 2026-07-31 |
| Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Collection - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia | Phase 2 | Suspended | University of Washington | 30 | 2026-05-08 | 2026-09-29 |
| Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma CD19 t-haNK- IV Administration, N-803, rituximab - Relapsed B-Cell Non-Hodgkin Lymphoma | Phase 2 | Not yet recruiting | ImmunityBio, Inc. | 20 | 2026-04-01 | 2026-03-17 |
| Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma Cyclophosphamide, Doxorubicin, Etoposide - B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 2 | Recruiting | University of Washington | 33 | 2026-03-30 | 2026-08-13 |
| CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL Capivasertib, Venetoclax, Rituximab - Leukemia, Lymphoma | Phase 1 / Phase 2 | Recruiting | University of Chicago | 104 | 2026-03-17 | 2026-03-04 |
| SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas SB-4826, Rituximab - Non Hodgkin Lymphoma, Solid Tumor | Phase 1 / Phase 2 | Recruiting | University of California, San Diego | 48 | 2026-02-18 | 2026-03-05 |
| Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma Venetoclax, Rituximab - Lymphoma, Marginal Zone Lymphoma | Phase 2 | Recruiting | Gottfried von Keudell, MD PhD | 33 | 2026-02-11 | 2026-03-13 |
Showing 20 of 645. Sign in to see all of them.
Lymphoma (139) · Leukemia, Lymphocytic, Chronic, B-Cell (137) · Lymphoma, Non-Hodgkin (124) · Lymphoma, Large B-Cell, Diffuse (119) · Lymphoma, Mantle-Cell (114) · Lymphoma, Follicular (104) · Lymphoma, B-Cell, Marginal Zone (71) · Burkitt Lymphoma (57) · Leukemia (57) · Waldenstrom Macroglobulinemia (53) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (52) · Lymphoma, B-Cell (43) · Hodgkin Disease (41) · Recurrence (25) · Lymphoma, Large-Cell, Immunoblastic (23)
M.D. Anderson Cancer Center (124) · National Cancer Institute (NCI) (69) · Mayo Clinic (15) · University of Washington (15) · Dana-Farber Cancer Institute (14) · Northwestern University (14) · City of Hope Medical Center (13) · Hoffmann-La Roche (12) · Fred Hutchinson Cancer Center (11) · Massachusetts General Hospital (10) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (9) · Weill Medical College of Cornell University (9) · University of Nebraska (8) · National Institute of Allergy and Infectious Diseases (NIAID) (7) · University of Miami (7)
United States (573) · Italy (35) · Canada (34) · Australia (32) · Spain (29) · France (28) · Germany (28) · United Kingdom (25) · Poland (21) · Czechia (20) · Belgium (19) · South Korea (18) · Brazil (15) · Austria (14) · Israel (14)
Elias Jabbour (7) · Chitra M. Hosing, MD (5) · E. Steve Woodle, MD (5) · Issa F. Khouri, MD (5) · Richard Burt, MD (5) · Ajay Gopal (4) · Andrew M. Evens, DO, MS (4) · Daniel O. Persky, MD (4) · Izidore S. Lossos, MD (4) · Julie M Vose, MD (4) · Alessandra Ferrajoli, MD (3) · Elias Jabbour, MD (3)
PMID 35787017, PMID 39319495, PMID 41671463, PMID 23834234, PMID 24224624, PMID 27695295, PMID 30125215, PMID 32126141, PMID 33735476, PMID 34515338, PMID 34634256, PMID 34797699, PMID 35952327, PMID 40550489, PMID 12011123, PMID 12353309, PMID 12907446, PMID 15389904, PMID 18713945, PMID 19118065, PMID 20023215, PMID 20038221, PMID 20039397, PMID 20039413, PMID 20058208, PMID 20142586, PMID 20223728, PMID 20647199, PMID 20956803, PMID 21073974, PMID 21098574, PMID 21239695, PMID 21325353, PMID 21360491, PMID 21440503, PMID 21478218, PMID 21508413, PMID 21756035, PMID 21816833, PMID 21821712, PMID 22133770, PMID 22231479, PMID 22269862, PMID 22282683, PMID 22357140, PMID 22371887, PMID 22563089, PMID 22586182, PMID 22677155, PMID 22734071
P30CA015704 (11), P30CA016672 (10), P30CA033572 (10), U10CA021115 (8), U10CA180821 (8), P30CA015083 (6), P30CA036727 (6), U10CA031946 (6), U10CA180820 (6), P30CA006973 (5), U10CA032102 (5), U10CA180888 (5), 2015 (4), P30CA060553 (4), U01CA076576 (4)